News After FDA exit, Peter Marks pops up at Lilly The ousted former director of CBER, Peter Marks, has joined Eli Lilly as head of molecular discovery and infectious disease research.
News GLP-1s from Novo, Lilly 'should be first-line in obesity' European doctors have said GLP-1 drugs are so effective in obesity that they should be the first choice drug treatment in almost all cases.
News Lilly names Houston as site for $6.5bn API facility Lilly has named Houston as the second of four locations for new manufacturing facilities that are central to a $27bn investment programme in the US.
News Oral GLP-1 contest ramps up with new Novo Nordisk data Novo Nordisk has trumpeted data showing oral Wegovy matched the injectable version in a phase 3 trial, ramping up pressure on rival Eli Lilly.
News Lilly weakens on data reveal for oral obesity candidate Eli Lilly is preparing to file for approval of its oral weight-loss drug orforglipron before year-end, but not all are convinced by the data.
News High dose of Wegovy drives weight loss to 19% A triple dose of Novo Nordisk's GLP-1 agonist Wegovy has shown improved activity on weight loss in an obesity trial versus the current formulation.
News Takeda gets first OK for orexin narcolepsy drug, in China China has become the first country to approve Takeda's first-in-class orexin agonist, oveporexton, for the sleep disorder narcolepsy.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
